Cyberonics gains US OK for new VNS therapy (vagus nerve stimulation):
This article was originally published in Clinica
Executive Summary
Cyberonics has gained US go-ahead to market a new line of implantable pacemaker-like devices for treating epilepsy. The new family includes a model 102 generator that is 33% thinner, 34% lighter and has 43% less volume than its predecessor, the model 101 generator, says the Texas, Houston firm. It also incorporates the model 302 lead, which is a single pin lead and which will be easier and faster to implant than its dual pin predecessor, the model 300 lead. Cyberonics' technology treats epilepsy using vagus nerve stimulation therapy (VNS).